IDEAYA Biosciences Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has appointed Stu Dorman as Chief Commercial Officer.   Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.   Prior to joining IDEAYA, he was the Vice President and head of the U.S. Oncology Business Unit at Gilead Sciences, where he built a leading oncology commercial orga...